Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics


Thermo Fisher Scientific Inc (TMO)

Today's Latest Price: $468.76 USD

3.50 (0.75%)

Updated Oct 21 6:40pm

Add TMO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

TMO Stock Summary

  • Thermo Fisher Scientific Inc's market capitalization of $185,436,487,144 is ahead of 99.19% of US-listed equities.
  • Thermo Fisher Scientific Inc's stock had its IPO on September 1, 1987, making it an older stock than 91.57% of US equities in our set.
  • The price/operating cash flow metric for Thermo Fisher Scientific Inc is higher than 89.01% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Thermo Fisher Scientific Inc are DHR, CMCSA, T, PEP, and NVO.
  • TMO's SEC filings can be seen here. And to visit Thermo Fisher Scientific Inc's official web site, go to www.thermofisher.com.

TMO Stock Price Chart Interactive Chart >

Price chart for TMO

TMO Price/Volume Stats

Current price $468.76 52-week high $478.99
Prev. close $465.26 52-week low $250.21
Day low $462.42 Volume 2,212,900
Day high $478.99 Avg. volume 1,654,520
50-day MA $434.58 Dividend yield 0.19%
200-day MA $363.39 Market Cap 185.44B

Thermo Fisher Scientific Inc (TMO) Company Bio


Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.

TMO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$468.76$156.99 -66%

We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:

  • The company's balance sheet shows it gets 90% of its capital from equity, and 10% of its capital from debt. Its equity weight surpasses that of 61% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 10% of the company's capital (with equity being the remaining amount). Approximately merely 24.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-67%
1%-67%
2%-66%
3%-66%
4%-66%
5%-65%

REPH, BAX, GMED, MDT, and OFIX can be thought of as valuation peers to TMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


TMO Latest News Stream


Event/Time News Detail
Loading, please wait...

TMO Latest Social Stream


Loading social stream, please wait...

View Full TMO Social Stream

Latest TMO News From Around the Web

Below are the latest news stories about Thermo Fisher Scientific Inc that investors may wish to consider to help them evaluate TMO as an investment opportunity.

Antinuclear Antibody Test Market (COVID - 19 Updates) 2020 to See Stunning Growth Worldwide, Leading Players -Alere Inc., Bio-Rad Laboratories, ERBA Diagnostics, Trinity Biotech, Thermo Fisher Scientific, Inc., Antibodies Incorporated

DBMR has added a new report titled Anti-Nuclear Antibody Test Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken

OpenPR | October 1, 2020

Immunohistochemistry Market To Witness Steady Growth With Danaher, Merck KGaA, Thermo Fisher Scientific, PerkinElmer, Abcam Plc, Agilent Technologies, Bio SB, Bio-Rad Laboratories, Cell Signalling Technology and F. Hoffmann-La Roche among others

A report by The Insight Partner's on the Immunohistochemistry Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the market

OpenPR | October 1, 2020

Global Clinical Oncology Next Generation Sequencing Market At A CAGR Of 13.90% Growth, Trends And Absolute Opportunity Up To 2027||Thermo Fisher Scientific, Myriad Genetics Inc., BGI, Perkin Elmer, Inc., Exosome Diagnostics Inc., GATC Biotech, DNASTAR, Qi

Data Bridge Market Research has recently added a concise research on the Clinical Oncology Next Generation Sequencing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges

OpenPR | October 1, 2020

Drug Discovery Services Market to Watch: Spotlight on Charles River Laboratories, Thermo Fisher Scientific, Merck

A new business intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Drug Discovery Services Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments.

OpenPR | September 30, 2020

Bioburden Testing Market Overview and Scope 2020 to 2027 | Key Players - Charles River Laboratories, Merck KGaA, SGS SA, Thermo Fisher Scientific

The latest study on the Bioburden Testing market published by the Reports and Data offers a deep understanding of the various market dynamics such as the challenges, drivers, trends, and opportunities. The report further elaborates on the micro and macro-economic

OpenPR | September 30, 2020

Read More 'TMO' Stories Here

TMO Price Returns

1-mo 8.95%
3-mo 15.41%
6-mo 42.78%
1-year 58.27%
3-year 143.19%
5-year 276.69%
YTD 44.57%
2019 45.55%
2018 18.21%
2017 35.03%
2016 -0.12%
2015 13.75%

TMO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TMO Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7657 seconds.